GlassScriptPhysician profile
Michael Louis Cher
NPI 1336187400
$12,287.11
in general payments reported to CMS, 2019-2025
24 companies · $769 in 2025
The $769 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,082 · 2020: $2,363 · 2021: $988 · 2022: $2,047 · 2023: $3,058 · 2024: $981 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,725 · Food and Beverage: $1,313 · Debt Forgiveness: $702 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,725.00 |
| Food and Beverage | $1,312.56 |
| Debt Forgiveness | $702.14 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $4,678.31 | 2022-2025 | Keytruda, Keytruda Qlex |
| Intuitive Surgical, INC. | $2,842.46 | 2019-2020 | |
| Astrazeneca Uk Limited | $1,074.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $875.26 | 2021-2025 | |
| Olympus America INC. | $717.35 | 2019-2024 | |
| Pfizer INC. | $447.12 | 2019-2025 | |
| Janssen Biotech, INC. | $341.45 | 2021-2025 | Tremfya, Erleada |
| Boston Scientific Corporation | $180.75 | 2019-2025 | Ams 700 |
| Blue Earth Diagnostics | $166.61 | 2019-2025 | Posluma |
| Palette Life Sciences, INC. | $166.42 | 2023 | |
| Ferring Pharmaceuticals INC. | $144.22 | 2024-2025 | Adstiladrin |
| Astellas Pharma US INC | $139.44 | 2020-2021 | |
| Immunitybio, INC. | $107.08 | 2025 | |
| Photocure INC | $94.59 | 2019 | |
| Abbvie INC. | $50.99 | 2023 | Lupron Depot |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $48.37 | 2024 | Provenge |
| Ucb, INC. | $45.18 | 2025 | Bimzelx |
| Myovant Sciences INC. | $44.23 | 2022 | |
| Sumitomo Pharma America, INC. | $40.71 | 2023 | Gemtesa, Orgovyx |
| Covidien LP | $21.27 | 2019 | |
| Ethicon US, LLC | $19.55 | 2020 | |
| Aurinia Pharma U.S., INC. | $16.14 | 2023 | Lupkynis |
| Tolmar, INC. | $14.09 | 2025 | Eligard, Jatenzo |
| Urogen Pharma, INC. | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.